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S342 Poster Session IIsmall intestine, colon and liver. 94% of mice within the allogeneic
group had severe cGVHD as defined by a clinical score above 0.6
by 28 days. At sacrifice, after day 35 post adaptive transfer, total
thymocyte numbers in mice with severe cGVHD were more than
20-fold depleted compared to syngeneic controls. Furthermore,
the double positive thymocyte cell population (CD4+ CD8+) was
most markedly reduced. Within the single positive thymocyte cell
subsets, the CD4+ proportion was more significantly diminished
than the CD8+ subset, although both subsets were dramatically re-
duced in cGVHD mice compared to syngeneic controls. Similarly,
in the spleen, live splenocytes were 3-fold depleted in animals with
severe cGVHD compared to syngeneic controls. Both CD4+ and
CD8+ T cells were significantly reduced with the recent thymic
emigrant (RTE) CD4 proportion (CD4+ CD44lo CCR7+) most
severely affected. Within CD4+ splenocytes, the total number of
T regulatory cells (CD4hi CD127lo Foxp3+) was not significantly
different betweenmice with cGVHDandwithout; however, the pro-
portion of Treg in animals with cGVHDwas significantly increased.
These data show that severe cGVHD is associated with impaired
thymopoiesis, with relative CD4 lymphopenia and diminished
RTE numbers. Conversely, preliminary data show that improved
thymopoiesis is associated with less severe cGVHD.527
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In the setting of unmanipulated non myeloablative (RIC) hemato-
poietic stem cell transplantation (HSCT) the possibility of biologi-
cally significant donor Killer cell immunoglobulin-like receptors
(KIRs)/HLA-C genomic (KIR-ligand) mismatched is potentially
important. To define the role of KIRs and KIR-ligands polymor-
phism we retrospectively analyzed 37 patients who underwent to
HSCT from HLA identical siblings for myeloid (n 5 16) or lym-
phoid malignancy. Pateints and donor KIR genes and ligandspoly-
morphisms were determined by PCR_SSP (14 genes plus 2
pseudogenes) and analyzed with different transplantation endpoints.
15/37 (40%) pairs were heterozygote for C1/C2 groups to confirm
a polymorphisms in KIR genes also in a HLA-identical sibling set-
ting. 12/37 (32%) and 9/37 (24%)were homozygotes respectively
for C1 andC2 groups therefore lacking the KIR-ligandC1 for donor
inhibitory KIR2DL2/3 and 20 the KIR-ligand C2 for donor inhibi-
tory KIR2DL1. We cannot find any correlation with acute or
chronic GVHD and OS. On the contrary the absence of patients’
HLA-C ligand for the corresponding donor inhibitory KIR genes
was associated to a better disease free survival (DFS) (9 months ver-
sus 3 months, chi square 3,9; p 5 0,04 logrank test). Moreover the
absence in the recipient of groupC1 ligandwas associated to a higher
probability of CMV reactivation (chi square 4,14; p5 0,038). Finally
the presence in the donor of at least one KIR inhibitory receptor sig-
nificantly improved DFS (chi square 3,9; p 5 0,039), irrespective to
the presence of its HLA class I ligand in the recipient. Despite the
small cohort of patient our data suggest a significant impact of inhib-
itory KIR on disease progression/relapse. Further studies are ongo-
ing to assess the role of activating KIR genes and to evaluate the
impact on survival of KIR haplotype. If confirmed in larger series
and in unrelated setting, the assessment of KIR genotype may be
used in a more sophisticade donor selection.528
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Chronic graft-versus-host disease (cGvHD) is amajor cause of late
mortality related to allogeneic hematopoietic stem cell transplanta-
tion (HSCT). The difficulty in standardizing cGvHD diagnostic
criteria, classification and severity led the National Institute of
Health (NIH) to develop a consensus project to these criteria.
This proposal included the scores of involved sites and the overall
assessment of severity classified as none, mild, moderate or severe.
Validation of the NIH classification translated is the goal of a pro-
spective multicenter study conducted by the GvHD Study Group
Brazil-Seattle (GEDECH) in a cohort of patients with cGvHD
transplanted in Brazil. The purpose of the workshop held in
CEMO was to train physical examination, standardize diagnostic
criteria and improve the filling of the detailed forms of the protocol
by the participants.
Methods: Five HSCT centers included representatives and the pro-
gram encompassed practical assessment of the cases, training with
the physiotherapists and discussion of results. Nine patients, under
informed consent, agreed to be photographed before and be exam-
ined, in private rooms, by groups of three professionals at a time.
The groups were supervised by a dermatologist and an oral medicine
doctor. They had 20 minutes to evaluate each patient and fill the
forms. In the next step, the patients were submitted to physiotherapy
evaluation for strength and 2-minute walk tests. Finally, using the
summary of the cases, the images and forms, the coordinators dis-
cussed in plenary session, aspects and difficulties associated with
this methodology and protocol.
Results: Participants did not scored the percentage grade of each
type of lesion and agreed that 20 minutes per patient were inade-
quate. Themain issues raised at the meeting were: difficulty in estab-
lishing the percentage of erythema in movable and nonmovable
sclerosis; the need to describe the changes in each region or the
dominant aspect of the lesion; the definition of poikiloderma; the
relationship between scale A (gravity) and scale B scores (symptoms)
in the overall assessment of cGvHD; disagreement in understanding
the degree of restriction of oral intake and between the methodolo-
gies used in strength and walk tests.
Conclusion: The workshop clarified several doubts about the clini-
cal assessment of cGvHD and suggestions will be applied in extend-
ing the protocol to other centers in Brazil.529
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The use of cord blood permits allogeneic transplantation with
a high degree of HLA disparity, but a lower incidence of GVHD
than expected for the degree of mismatch. Nonetheless, the inci-
dence of grade II-IV acute GVHD (aGVHD) can be as high as
58%, and may be increased after double unit CBT. However,
GVHD after CBT may also be more responsive to corticosteroids
than that after allografts using adult donors. Therefore, we have in-
vestigated the treatment of grade II acute GI GVHD with single
agent budesonide (9mg daily) as first line therapy. We evaluated
the incidence, nature, and treatment response of grade II-IV
aGVHD in 101 double unit CBT recipients that were transplanted
between 10/01/05-05/30/10. Conditioning was myeloablative
(75%), or non-myeloablative (25%), and no patient received anti-
thymocyte globulin. GVHD prophylaxis consisted of a calcineurin
Table 1. Summary of aGVHD severity and treatment response (N549)
Budesonide Single
Agent (N520)
Systemic
Corticosteroids (N525)
No Therapy or
Topical Steroids (N54)
Total
(N549)
N (%) Organs Involved
Skin Alone - 5 (20%) 3 (75%) 8 (16%)
GI Alone 9 (45%) 2 (8%) - 11 (23%)
Liver Alone - 1 (4%) 1 (25%) 2 (4%)
Skin/GI 9 (45%) 10 (40%) - 19 (39%)
GI/Liver 1 (5%) 3 (12%) - 4 (8%)
Skin/GI/Liver 1 (5%) 5 (20%) - 5 (10%)
N (%) Grade aGVHD
II 20 (100%) 5 (20%) 3 (75%) 28 (57%)
III - 15 (60%) 1 (25%) 16 (33%)
IV - 5 (20%) - 5 (10%)
N (%) Day 28 Treatment Response
CR/PR 7(35%)/9(45%) 8(32%)/12(48%) 3(75%)/1(25%) 40 (82%)
hPR 4 (20%) 5 (20%) - 9 (18%)
N (%) Day 56 Treatment Response
CR/PR 10(50%)/7(35%) 7(28%)/13(52%) 4 (100%)/ 0 41 (84%)
hPR 3 (15%) 5 (20%) - 8 (16%)
Poster Session II S343inhibitor and mycophenolate mofetil. Forty-nine patients developed
grade II-IV aGVHD by day 100 for a cumulative incidence of 50%
(95%CI:40-60) grade II-IV and 26% (95%CI:16-35) grade III-IV,
respectively. The median time of aGVHD onset was 39 days (range
14-99). Organs most commonly affected were skin/ GI (39%), GI
alone (23%), and skin alone (16%). Single agent budesonide was
used for the treatment of 20 patients with initial grade II GI aGVHD
(Table 1). Complete or partial responses (CR/PR) were observed by
day 28 in the majority (n5 16, 80%), which were maintained at day
56. Notably, only 3 of 20 budesonide patients required salvage with
systemic corticosteroids (2 responded, 1 progressed). Twenty-five
patients with predominantly grade III-IV aGVHD received systemic
corticosteroids from the outset of therapy (Table 1). CR or PR was
obtained in 80% by day 56. With a median follow-up of 24 months
(range 4.5-60.5), the 1-year cumulative incidence of ongoing late
acute or chronic GVHD was 35% (95%CI:26-45), and the 1-year
progression-free survival is 65% (95%CI:56-75). Seven patients
have died of GVHD, 2 patients initially treated with budesonide,
and 5 with systemic corticosteroids. We conclude that double unit
CBT is associated with a significant incidence of grade II-IV
aGVHDand new strategies for prophylaxis are warranted.However,
a significant number of patients with grade II GI aGVHD can be
treated successfully with budesonide alone, and this approach war-
rants prospective investigation. Finally, new therapies are needed
for CBT recipients with more severe aGVHD.530
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cGVHD is the most serious and common long-term complication
of this allogeneic transplantation, occurring in 30-70% of patients
surviving more than 100 days. cGVHD is associated with a high de-
gree of morbidity and mortality and remains a major cause of late
death. Initial therapy involves systemic corticosteroids which can
contribute to further complications. In cases where steroids are inef-
fective or poorly tolerated, effective therapeutic options are limited.
Anecdotal reports of myeloma patients treated with bortezomib after
transplantation have shown improvement in cGVHD.
We have begun a trial of bortezomib in patients with steroid-re-
fractory cGVHD. Patients receive 1.6 mg/m2 q wk x 4 followed by
one week of rest, for up to six cycles. To date 9 patients have beenentered on trial and 5 have completed between 2 and 4 cycles. The
treatment has been well tolerated with no grade 3 or higher adverse
events (AE). AE have been grade 1-2 nausea (3), grade 1-2 diarrhea
(6) grade 1-2 fatigue (4), one grade 2 transient neuropathy has
been reported. There have been 3 treatment delays (1 patient) and
dose reduction due to decreased hemoglobin and one due to tran-
sient neuropathy.
Subjective improvement has reported in 6 of the first 8 patients,
Improvement in general well-being has been noted as early as the
first treatment. Two patients have had improvement in severe long
standing sclerotic changes, including the ability to extend fingers
that had long been contracted. Average Rodnan scores on 5 patients
with sclerosis completing 2 or more cycles of therapy decreased from
(3169.6 to 13.867.5) One patient with non-healing suppurating le-
sions of his lower extremities has shownmarked healing, another has
significant decrease in chronic diarrhea.
Weekly bortezomib for cGVHD appears to be well tolerated and
results in early improvement in long standing refractory disease. Our
plan is to enroll twenty-five patients to determine if these encourag-
ing findings are sustainable.531
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Background: The great variability in the diagnosis of chronic
GVHD and the long period required to complete clinical trials
